GX Genomics & Biotechnology ETF (GNOM)

$9.70 0.01 (0.10%)

9:39 EDT GNOM Stock Quote Delayed 30 Minutes

3 Stocks That Could Be the Next Big Thing in Gene Editing

By Ian Cooper, InvestorPlace Contributor Mar 21, 2024

Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.

3 Gene Editing Stocks With Unprecedented Surge Potential

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

3 Gene Editing Stocks to Generate Super-Charged Gains

More Articles

Volume:

Previous Close -

Market Cap 324.16M

PE Ratio -4.04

EPS -2.4

Volume (Avg. Vol.) 12,877

Day's Range $9.65 - $9.75

52-Week Range $8.63 - $13.33

Dividend & Yield N/A (N/A)

GNOM Stock Predictions, Articles, and GX Genomics & Biotechnology ETF News

From InvestorPlace
From the Web

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

By Ian Cooper, InvestorPlace Contributor Mar 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

3 Gene Editing Stocks With the Best Long-Term Potential

By Muslim Farooque, InvestorPlace Contributor Jan 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

By Ian Cooper, InvestorPlace Contributor Jan 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in ten years.

7 Biotech ETFs That Should Remain Healthy

By Todd Shriber, InvestorPlace Contributor Aug 5, 2019

The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.

ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM

From Talk Markets Oct 21, 2021

The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage.

A Comprehensive Guide To Genomic ETFs

From Talk Markets Jul 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.

Top-Performing Biotech ETFs of Last Week

From Talk Markets Jun 15, 2021

Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week.

ETF Battles ARKG Vs. GNOM - What's The Better Genomic/Biotech Play?

From Talk Markets Jun 4, 2021

Each ETF is judged against the other in key categories like cost, exposure strategy, performance, and a mystery category.

4 Best ETF Sectors Of Q4

From Talk Markets Dec 27, 2020

Small caps beat the major indexes, but the sectors that did even better are clean energy, regional banking, cannabis, and biotech.

ETFs in Focus on Bayer's Bet on Gene Therapy

From Talk Markets Oct 30, 2020

Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon.

ADVERTISEMENT